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background: There is limited head-to-head data on late stent-related outcomes for everolimus-eluting stent (EES) and sirolimus-eluting stent (SES).
methods: In the SORT OUT (Scandinavian Organization for Randomized Trials with Clinical Outcome) IV trial we prospectively randomized 2,774 
patients. The SORT OUT IV trial demonstrated non-inferiority of the EES to the SES at 9 months. Follow-up through 4 years is complete in 2,770 
99.9%). The 4-year pre-specified endpoint was a composite of safety and efficacy (MACE: cardiac death, myocardial infarction and target vessel 
revascularization and definite stent thrombosis) and the safety endpoint of interest was definite stent thrombosis.
results: At 4-year MACE rate was lower in the EES group (11.8%) compared to the SES group (14.7%) (hazard ratio (HR) 0.80, 95% confidence 
interval (CI) 0.65-0.98). Stent-related composite outcomes (cardiac death, target vessel MI, or symptom-driven target lesion revascularization) was 
lower in EES treated patients (7.8%) compared to SES treated patients (9.8%) (HR 0.79, 95% CI 0.62-1.02). Definite stent thrombosis occurred 
within 4 years in 31 patients (1.1%). Overall rate of definite stent thrombosis was lower in the EES group (0.3% versus 2.0%, (HR=0.15, 95% CI 0.05-
0.42)).
EES SES HR 95% CI
Definite stent thrombosis
0-4 years 4 (0.3%) 27 (2.0%) 0.15 (0.05-0.42)
0-1 year 2 (0.1%) 9 (0.7%)
1-2 years 1 (0.1%) 4 (0.3%)
2-3 years 0 (0.0%) 7 (0.5%)
3-4 years 1 (0.1%) 7 (0.5%)
Very late stent thrombosis 2 (0.1%) 18 (1.3%) 0.11 (0.03-0.47)
conclusion: A significant reduction of overall and very late definite stent thrombosis was found in the EES group which was largely attributable to a 
lower risk of very late definite stent thrombosis.
